Correction

In an article1 titled “Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo” by Chuanzhen Hu, Xu Chen, Junxiang Wen, Liangzhi Gong, Zhuochao Liu, Jun Wang, Jing Liang, Fangqiong Hu, Qi Zhou, Li Wei, Yuhui Shen and Weibin Zhang, the following should be replaced:

• aIn the second paragraph under “Materials and Methods,” the number of OS cell lines should be amended from six to five, and the details for MG63.2 cell line and HUVECs should be added so that the first two sentences of this paragraph will read as:

Osteosarcoma cell lines. Five OS cell lines (143B, SAOS2, MG63, HOS, and U2OS) were purchased from ATCC (Manassas, VA, USA). The MG63.2 cell line was kindly donated by Dr. Yingqi Hua (Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine). HUVECs was kindly donated by Shanghai Institute of Hypertension.

• bIn the sixth paragraph under “Materials and Methods,” the name of the detection kit should be amended from “PE Annexin V Apoptosis Detection Kit” to “PI Annexin V Apoptosis Detection Kit” so that the first sentence reads as:

Apoptosis. Apoptosis assay was undertaken with a PI Annexin V Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, USA) to identify apoptotic nuclei.

• cThe concentrations listed in the legend for Figure. 3(a) should be amended from (1, 2.5, and 5 μM) to (1, 2, and 4 μM) so that the sentence reads as:

(a) WELL5, MG63, 143B, and U2OS cells treated with PF562271 for 48 h at different concentrations (1, 2, and 4 μM) relative to DMSO was analyzed by flow cytometry after staining with annexin V‐FITC/propidium iodide.

• dThe labelling of 143B and MG63 osteosarcoma cells in Figure 4(b) and (c) is incorrect. The correct Figure 4 is shown above:

The authors apologize for these errors.